Finance

Sepracor reports total revenues of $357.2 million in Q4 2006, $1,196.5 million for year

Published in Lab Law Weekly, March 2nd, 2007

Sepracor Inc. (SEPR) reported consolidated revenues for the fourth quarter ended December 31, 2006, of approximately $357.2 million, of which revenues from Sepracor's pharmaceutical product sales were approximately $348.8 million.

Of the total pharmaceutical sales, Xopenex brand levalbuterol HCl inhalation solution revenues were $179.9 million, Xopenex HFA brand levalbuterol tartrate inhalation aerosol MDI revenues were $20.9 million, and Lunesta brand eszopiclone revenues were $148.0 million.

Net income for the fourth quarter of 2006 was approximately $99.1 million. Reported results for the fourth quarter of 2006 included charges of $13.8 million...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-03-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry